Last updated: 2026-10-13 21:47:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Arcutis Biotherapeutics, Inc. (ARQT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $26.11, with a market capitalization of $3.34B and a P/E ratio of 115.56. Over the past 52 weeks, its price has ranged from $19.30 to $31.77. This page covers its latest market performance, valuation, price trends and company information.
$3.34B | |
$25.93 | |
$40.88 | |
$1.76 | |
$26.22 | |
1.51M | |
2.26M | |
115.56 | |
$31.77 | |
$19.30 | |
-- | |
-- |
Arcutis Biotherapeutics, Inc. (ARQT) is trading at $26.00 in after-hours trading as of 2026-10-13 21:45:00, down 0.83% ($0.22) from the regular-session close of $26.22.
After-hours trading shows how investors are pricing ARQT after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Arcutis Biotherapeutics, Inc. (ARQT) moved from $25.16 to $26.11, representing a gain of 3.76% ($0.95).
The stock traded between $23.37 and $26.97 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 2.04 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 54.6%
ARQT is currently trading at $26.11, placing it 54.6% of the way from its 52-week low of $19.30 to its 52-week high of $31.77. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 354 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Arcutis Biotherapeutics, Inc. (ARQT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.